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We evaluated uptake and diagnostic outcomes 
of voluntary hepatitis B (HBV) and C virus (HCV) 
screening offered during routine tuberculosis entry 
screening to migrants in Gelderland and Amsterdam, 
the Netherlands, between 2013 and 2015. In Amsterdam, 
HIV screening was also offered. Overall, 54% (461/859) 
accepted screening. Prevalence of chronic HBV infec-
tion (HBsAg-positive) and HCV exposure (anti-HCV-
positive) in Gelderland was 4.48% (9/201; 95% 
confidence interval (CI): 2.37–8.29) and 0.99% (2/203; 
95% CI: 0.27–3.52), respectively, all infections were 
newly diagnosed. Prevalence of chronic HBV infec-
tion, HCV exposure and chronic HCV infection (HCV 
RNA-positive) in Amsterdam was 0.39% (1/256; 95% 
CI: 0.07–2.18), 1.17% (3/256; 95% CI: 0.40–3.39) and 
0.39% (1/256; 95% CI: 0.07–2.18), respectively, with 
all chronic HBV/HCV infections previously diagnosed. 
No HIV infections were found. In univariate analyses, 
newly diagnosed chronic HBV infection was more 
likely in participants migrating for reasons other than 
work or study (4.35% vs 0.83%; odds ratio (OR) = 5.45; 
95% CI: 1.12–26.60) and was less likely in participants 
in Amsterdam than Gelderland (0.00% vs 4.48%; 
OR = 0.04; 95% CI: 0.00–0.69). Regional differences 
in HBV prevalence might be explained by differences 
in the populations entering compulsory tuberculosis 
screening. Prescreening selection of migrants based 
on risk factors merits further exploration.
Introduction 
In the Netherlands, it is estimated that 39,000 indi-
viduals have a chronic hepatitis B virus (HBV) infection 
(HBsAg-positive) [1], 19,000 have a chronic hepatitis C 
virus (HCV) infection (HCV RNA-positive) [2] and 23,000 
have a human immunodeficiency virus (HIV) infec-
tion [3]. A large proportion of chronic HBV infections 
(ca 50%) and past/chronic HCV infections (ca 40%; 
anti-HCV positive) are estimated to be found among 
migrants coming from countries endemic for HBV or 
HCV, respectively, and ca 40% of HIV patients in clini-
cal care are migrants [1,3,4].
Currently, effective treatment options are available 
for HBV, HCV and HIV infections. However, the often 
asymptomatic onset of these infections and disease 
development of HBV and HCV infections may delay 
diagnosis and therefore treatment. Screening for HBV, 
HCV and HIV can identify undiagnosed infections, 
improving the prognosis and limiting transmission to 
others by linking infected persons to treatment and 
care at an early stage [5-8]. To find undiagnosed cases, 
several HBV and HCV screening programmes, mostly 
community-based, have targeted specific groups of 
migrants in the Netherlands in recent years [9]. The 
prevalence found in those programmes ranged from 
0% to 9.5% for chronic HBV infection (HBsAg-positive) 
and from 0% to 6.5% for HCV exposure (anti-HCV posi-
tive), depending on the target group and the recruit-
ment strategy [9,10-18]. However, these programmes 
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were not sustainable, because they were done only 
once, highly labour-intensive and tailored to particu-
lar migrant groups and residential areas [9]. The inte-
gration of screening into existing healthcare services 
could increase long-term sustainability and continuity 
in reaching and screening key populations. In addition, 
integration would most probably make such screening 
programmes more cost-effective because fewer addi-
tional resources would be required. As countries with 
high endemicity for tuberculosis (TB) largely overlap 
with countries with a high HBV, HCV or HIV prevalence, 
screening for these viruses could be integrated into the 
existing TB entry screening performed by TB depart-
ments of the public health services in the Netherlands. 
TB entry screening is compulsory for migrants from 
outside the European Union (EU) who intend to stay 
in the Netherlands for more than three months [19]. 
Since January 2015, the compulsory screening has 
been further restricted to non-EU migrants originating 
from countries with TB incidence of more than 50 per 
100,000 inhabitants per year.
To evaluate whether integrated TB, HBV, HCV and HIV 
screening is effective and acceptable among migrants, 
we initiated a screening project offering additional vol-
untary HBV, HCV and HIV screening to migrants under-
going compulsory TB screening. We studied the uptake 
of screening and the prevalence and determinants of 
newly diagnosed HBV, HCV and HIV infections. The 
resulting data can be used to support policy-makers in 
the decision on integrating screening for these infec-
tions into the existing TB entry screening for migrants.
Figure 
Recruitment strategy and clinical outcomes of hepatitis B, hepatitis C and HIV screening offered to migrants attending 
compulsory tuberculosis entry screening at the public health services, the Netherlands, 2013–2015 (n = 859)
968 migrants aged 18 years or older attended the
tuberculosis clinic of the Public Health Service of
Gelderland or Amsterdam during the screening period.
859 migrants were oﬀered voluntary HBV, HCV and
HIVa screening
461 migrants (54%) accepted screening
In 2 persons, we were unable to draw blood
In 2 persons, HBsAg was not determined
1 person opted out of HIV screeninga
HIV infectiona
0/255 HIV-positive
HCV infection
5/459 (1.09%; 95% CI: 0.47-2.52) anti-HCV-positive
1/256 (0.39%; 95% CI: 0.07-2.18) HCV RNA-positivec
HBV infection
10/457 (2.19%; 95% CI: 1.19-3.98) HBsAg-positive
- 9 HBsAg-positive cases were previously undiagnosed
- 1 HBsAg-positive case was previously
- In Gelderland, all anti-HCV-positive cases (n=2) were
   previously undiagnosed
- In Amsterdam, all HCV RNA-positive cases (n=1) were
   previously diagnosed but had discontinued treatment 
   and were not in clinical care
457 were screened for chronic HBV infection (HBsAg)
459 were screened for HCV exposure (anti-HCV)
256 were screened for chronic HCV infection (HCV-RNA)c
255 were screened for HIV infectiona
109 migrants were excluded:
- 58 were planning to stay < 6 months in the
   Netherlands (Amsterdam)
- 35 were vaccinated against HBV infection 
   (Gelderland)
- 16 were not able to read the project information
Reasons for declining screeningb (n=398):
- Already been tested (35%; n=141)
- Time constraints (18%; n=70)
- Fear of blood-drawing (14%; n=54)
- Does not want to be tested (12%; n=46)
- No specific reason for decline (7%; n=29)
- Does not feel at risk (4%; n=17)
- Afraid (reason not specified) (4%; n=17)
- Needs more time to decide (3%; n=13)
- Other reasons (8%; n=33)
- Missing (3%; n=11)
HBV: hepatitis B virus, HCV: hepatitis C virus, HIV: human immunodeficiency virus. 
a HIV screening was only offered at the Public Health Service of Amsterdam.
b The percentages add up to >100% as participants could have mentioned more than one reason for declining screening.
c HCV RNA was only tested in Amsterdam.
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Table 1
Characteristics of migrants who accepted hepatitis B, hepatitis C and HIVa screening during compulsory tuberculosis 
screening at public health services, the Netherlands 2013–2015 (n = 459)
Total Gelderland Amsterdam
p value
(n = 459) (n = 203) (n = 256)
median IQR median IQR Median IQR
Age (years) 29 26-35 28 25-34 30 27-36 < 0.001
n % n % N %
Sex
Male 211 45.97 92 45.32 119 46.48
0.804
Female 248 54.03 111 54.68 137 53.52
Reason for migration
Work or study 244 53.16 93 45.81 151 58.98
< 0.001Other (e.g. family reunification) 162 35.29 110 54.19 52 20.31
Missing 53 11.55 0 0.00 53 20.70
Intended length of stay in the Netherlandsb
< 1 year
NA
19 9.36
NA NA
1–2 years 28 13.79
> 2 years 116 57.14
Missing 40 19.70
Region of origin (categorised according to WHO regions)
South-East Asia 154 33.55 47 23.15 107 41.80
< 0.001
Europe (southern/eastern) 95 20.70 42 20.69 53 20.70
Western Pacific 86 18.74 42 20.69 44 17.19
Africa 61 13.29 32 15.76 29 11.33
Eastern Mediterranean 39 8.50 22 10.84 17 6.64
Americas (Latin America/Caribbean) 23 5.01 18 8.87 5 1.95
Missing 1 0.22 0 0.00 1 0.39
Estimated HBV prevalence (HBsAg-positive) in the country of originc
< 2% 204 44.44 66 32.51 138 53.91
< 0.001≥ 2% 252 54.90 136 67.00 116 45.31
Missing 3 0.65 1 0.49 2 0.78
Estimated HCV prevalence (HCV-RNA positive) in the country of originc
< 2.5% 398 86.71 179 88.18 219 85.55
0.470≥ 2.5% 60 13.07 24 11.82 36 14.06
Missing 1 0.22 0 0.00 1 0.39
Estimated HIV prevalence in the country of originc
< 2.12% 403 87.80 173 85.22 230 89.84
0.104≥ 2.12% 55 11.98 30 14.78 25 9.77
Missing 1 0.22 0 0.00 1 0.39
Registered at a general practitioner in the Netherlandsd
No
NA NA
174 67.97
NAYes 78 30.47
Missing 4 1.56
Registered for health insurance coverage in the Netherlandsd
No
NA NA
72 28.13
NA
Yes, Dutch health insurance 122 47.66
Yes, foreign health insurance 27 10.55
Yes, student health insurance 10 3.91
Yes, but unknown which one 21 8.20
Missing 4 1.56
HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IQR: interquartile range; NA: not applicable (not measured); WHO: World 
Health Organization.
a HIV screening was included only in Amsterdam.
b Measured only among participants from Gelderland.
c Participants were grouped and categorised according to the estimated HBV, HCV and HIV prevalence reported by Schweitzer et al. [21], Gower et al. [22] and the 
Global Burden of Disease Study [23], respectively.
d Measured only among participants from Amsterdam.
This table excludes migrants who accepted screening but in whom blood-drawing failed (n = 2).
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Methods 
Study population
This screening project was performed at five TB 
departments of the public health services in the 
Netherlands (a convenience sample: four in the prov-
ince of Gelderland, one in the city of Amsterdam). 
In Gelderland, recruitment continued until at least 
352 TB department visitors had been asked to par-
ticipate (October 2013 to February 2015). The sample 
size was based on an expected prevalence of 4.5% 
HBsAg-positive samples, with a 2.5% margin of error 
at an alpha of 0.05 in order to detect a minimum HBsAg 
positivity rate of at least 2%. In Amsterdam, we used 
Table 2
Univariate analysis of potential determinants of newly diagnosed chronic hepatitis B infection among migrants who 
accepted hepatitis B, hepatitis C and HIVa screening during compulsory tuberculosis entry screening at public health 
services, the Netherlands, 2013–2015 (n = 456)
Newly diagnosed chronic HBV infection Univariate analyses
p value
n/N % OR 95% CI
Sex
Male 3/210 1.43 1 Ref 0.433 
Female 6/246 2.44 1.72 0.43–6.98
Age
18–26 years 2/125 1.60 1 Ref 0.165 
 
 27–32 years 6/175 3.43 2.18 0.43–11.00
> 32 years 1/156 0.64 0.40 0.04–4.43
Reason for migration
Work or study 2/242 0.83 1 Ref 0.019 
 
 Other (e.g. family reunification) 7/161 4.35 5.45 1.12–26.60
Missing 0/53 0.00 b b
Intended length of stay in the Netherlandsc
< 1 year 0/19 0.00 1 Ref 0.399 
 
 
 
 
1–2 years 2/28 7.14 3.68 0.17–81.03
> 2 years 3/114 2.63 1.22 0.06–24.64
Missing 4/40 10.00 b b
Region of origin (categorised according to WHO regions)
South-East Asia 3/154 1.95 1 Ref 0.976 
 
 
 
 
 
 
 
 
 
 
Europe (southern/eastern) 3/95 3.16 1.64 0.36–7.37
Western Pacific 2/84 2.38 1.31 0.25–6.80
Africa 1/60 1.67 1.09 0.16–7.56
Eastern Mediterranean 0/39 0.00 0.55 0.28–10.83
Americas (Latin America/ Caribbean) 0/23 0.00 0.92 0.05–18.40
Missing 0/1 0.00 b b
Estimated HBV prevalence (HBsAg-positive) in the country of origind
< 2% 3/204 1.47 1 Ref 0.664 
 
 ≥ 2% 5/249 2.01 1.37 0.32–5.82
Missing 1/3 33.33 b b
Location of screening
Gelderland 9/201 4.48 1 Ref
0.026
Amsterdam 0/255 0.00 0.04 0.00-0.69
CI: confidence interval; HBV: hepatitis B virus; Ref: reference value, OR: odds ratio; WHO: World Health Organization.
a HIV screening was included only in Amsterdam.
b Missing categories were excluded from the analysis.
c Measured only among participants from Gelderland.
d Participants were grouped and categorised according to the estimated HBV prevalence reported by Schweitzer [21].
This table excludes migrants who accepted screening but in whom blood drawing failed (n = 2), participants in which HBsAg was not 
determined (n = 2), and the previously diagnosed HBV-infected participant (n = 1).
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a convenience sample of 250 participants, and recruit-
ment took place from July 2015 through August 2015. 
Migrants visiting these TB departments have migrated 
primarily for work, study or family reunification. Asylum 
seekers are usually screened at TB departments in 
refugee centres and were therefore not included in 
this project. HBV and HCV screening was offered to all 
migrants attending the five TB departments for their 
compulsory TB entry screening. In Amsterdam, HIV 
screening was also offered.
Recruitment
Migrants 18 years or older who were able to read the 
project information were eligible for HBV, HCV and 
HIV screening. In Gelderland, migrants were excluded 
if they had been vaccinated against HBV, whereas in 
Amsterdam, HBV vaccination history was not recorded. 
In Amsterdam, migrants were excluded if they intended 
to stay less than 6 months in the Netherlands, in order 
to ensure that those testing positive could be linked to 
care in the Netherlands.
All participants provided written informed consent. The 
project was conducted according to the ethical guide-
lines of the 1975 Declaration of Helsinki. The local med-
ical ethics committee of the region Arnhem-Nijmegen 
(Radboud University Medical Center) approved the 
screening project (2013/172).
Screening procedure
In Gelderland, migrants received information about 
HBV, HCV and HIV screening before their appoint-
ment for TB screening by post. In Amsterdam, where 
only walk-in TB consultations are provided, migrants 
received information about HBV, HCV and HIV screen-
ing on arrival for TB screening. Project information was 
available in Dutch and English and, in Amsterdam, also 
in Arabic, Chinese, French, Portuguese, Russian and 
Spanish. After eligible migrants had completed their 
routine TB screening, they were asked to participate 
in this screening project and the informed consent 
form was signed. Blood was drawn from those who 
accepted HBV, HCV and HIV screening. In Amsterdam, 
participants could opt out of testing for any of the three 
infections individually.
From all eligible migrants, the following data were col-
lected during their TB screening visit: age, sex, country 
of origin and intended length of stay in the Netherlands. 
In Gelderland, reason for migration was included as an 
open-ended question. In Amsterdam, data on the rea-
son for migration were derived from migration forms 
that categorised answers as work/study or other (e.g. 
partner or family reunification, but not further speci-
fied). In Amsterdam, participants were also asked 
whether they were currently registered with a general 
practitioner (GP) in the Netherlands and whether they 
had health insurance. In both regions, all persons who 
declined HBV, HCV and HIV screening were asked for 
the reason for non-participation, using an open-ended 
question.
Laboratory testing
In Gelderland, blood samples were tested for anti-HBc 
and anti-HCV at the laboratory of the Gelre Hospital 
in Apeldoorn (ADVIA Centaur, Siemens, Germany), 
Meander Medical Center in Amersfoort (ARCHITECT, 
Abbott, United States) or Slingeland Hospital in 
Doetinchem (Cobas 6000, Roche, Switzerland). 
Samples positive for anti-HBc were further tested for 
HBsAg, anti-HBs, anti-HBe and HBeAg.
In Amsterdam, blood samples were first tested for 
HBsAg, anti-HCV, and HIV antigen or antibodies 
(LIAISON XL MUREX, DiaSorin, Italy) at the laboratory 
of the public health service of Amsterdam. Samples 
positive for HBsAg were further tested for anti-HBc, 
anti-HBs, anti-HBe and HBeAg. Samples positive 
for anti-HCV were further tested for HCV RNA (HCV 
Quantitative test, version 2.0, Cobas AmpliPrep/Cobas 
TaqMan, Roche, Switzerland). Samples positive for HIV 
antigen or antibodies were confirmed with Western blot 
(INNO-LIA HIV I/II Score, Innogenetics, Belgium), HIV-1 
p24 antigen test (Vidas HIV P24, Bio Merieux) and HIV 
viral-load testing (HI2CAP, Roche, Switzerland).
Persons found HBsAg-positive were considered to have 
a chronic HBV infection. As the incidence of acute HBV 
infection in the Netherlands is very low, also among 
migrants, we assumed all HBsAg-positive persons to 
be chronically infected. Persons found positive for anti-
HCV were considered exposed to HCV, persons positive 
for HCV RNA were considered to have a chronic HCV 
infection, and persons with confirmed HIV antigen- or 
antibody-positive tests were considered HIV-positive.
Follow-up procedure
Participants who did not have a chronic HBV infection, 
an HCV infection or HIV infection received a letter with 
their test results. Participants with an infection were 
verbally informed of their test results by a nurse or 
doctor at the public health service and referred to their 
GP, the first point of care in the Netherlands. At the TB 
clinics in Gelderland, HCV RNA testing for those who 
tested anti-HCV positive was not included. These par-
ticipants were referred to their GP for further testing. In 
accordance with the Dutch Public Health Act, chronic 
HBV infections were reported to the department of 
infectious diseases of the public health service in each 
patient’s hometown, to enable contact tracing.
In Amsterdam, participants with a chronic HBV, chronic 
HCV or HIV infection were contacted 3 and 6 months 
after they had received their results to ask if they had 
received follow-up care. We collected data on whether 
they had started treatment and whether they had vis-
ited their GP or a specialist.
Statistical analyses
We described the following characteristics for all eligi-
ble migrants: age, sex, reason for migration, intended 
length of stay, region of origin, registration at GP, 
health insurance coverage, and HBV, HCV and HCV 
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prevalence in the country of origin. Countries of origin 
were grouped into regions of origin according to the 
World Health Organization classification [20]. We also 
created three dichotomous variables (low-endemic vs 
intermediate/high-endemic) related to the HBV, HCV 
and HIV prevalence in the country of origin, using esti-
mates by Schweitzer et al. [21], Gower et al. [22] and 
the Global Burden of Disease Study [23], respectively. 
Based on the categorisation of the reported estimates 
in the literature cut-off points of 2.0%, 2.5% and 2.12% 
were used to dichotomise HBV, HCV and HIV preva-
lence, respectively.
We compared the characteristics between those who 
refused and those who accepted the additional HBV, 
HCV and HIV screening, and also between partici-
pants recruited in Gelderland and those recruited in 
Amsterdam, using chi-squared tests for categorical 
variables and Mann–Whitney U test for continuous 
variables. We calculated the screening uptake (defined 
as the number of migrants who accepted screening 
among all the eligible persons) and described rea-
sons for declining screening. In all analyses, the four 
sites in Gelderland were treated as one, as all used 
the same recruitment strategy and served comparable 
populations.
HBsAg, anti-HCV, HCV RNA and HIV prevalence and 
corresponding 95% confidence intervals (CI) were cal-
culated using Wilson intervals. Using univariate logis-
tic regression analyses, we examined determinants of 
a newly diagnosed chronic HBV infection, excluding 
persons with a previously diagnosed HBV infection. 
Penalised logistic regression was used to calculate 
odds ratios (OR) and 95% CI in a table with a zero cell 
count.
In all analyses, cases with unknown or missing data 
were excluded. Analyses were performed using STATA 
Intercooled 13.1 (STATA Corporation, College Station, 
United States). Statistical significance was set at 
p < 0.05.
Results 
Characteristics of participants
A total of 968 migrants, aged 18 years or older, 
attended the five TB departments for their TB entry 
screening (Figure).
In Gelderland, 35 migrants were excluded because of 
prior HBV vaccination. In Amsterdam, 58 migrants were 
excluded because they intended to stay less than 6 
months in the Netherlands. Furthermore, 16 migrants 
were excluded because they were unable to read the 
project information. Of 859 eligible migrants who were 
asked to participate, 461 (54%) accepted HBV or HCV 
(and in Amsterdam, HIV) screening. There was no signif-
icant difference between response rates in Gelderland 
vs Amsterdam (57% vs 51%; p = 0.113). Sex, age, region 
of origin, reason for migration, intended length of stay 
in the Netherlands and HBV and HCV prevalence in the 
country of origin did not significantly differ between 
those who refused and those who accepted screen-
ing. Participants who originated from a country with an 
estimated HIV prevalence of ≥ 2.12% were more likely 
to accept screening compared with participants from 
a country with an estimated HIV prevalence of < 2.12% 
(65% vs 52%; p = 0.022). The most commonly mentioned 
reasons for declining screening were: already been 
tested (35%; 141/398), time constraints (18%; 70/398) 
and fear of blood-drawing (14%; 54/398). Already been 
tested as a reason for declining was more likely to be 
reported by migrants from South-East Asia compared 
with other regions (50% vs 10–36%; p < 0.001) and by 
migrants visiting the TB clinic in Amsterdam compared 
with Gelderland (42% vs 25%; p < 0.001).
Two of the 461 migrants who accepted screening were 
ultimately not screened because blood-drawing failed. 
For 459 screened participants (203 in Gelderland and 
256 in Amsterdam), median age was 29 years (inter-
quartile range (IQR): 26–35 years) and 46% were male 
(Table 1). About half of the participants migrated for 
work/study (53%), and a third (34%) of all participants 
originated from South-East Asia. Only one person 
(1/256; 0.39%) in Amsterdam opted out of HIV testing, 
citing a low risk perception.
Participants in Gelderland were younger and more 
often had migrated for reasons other than work/study 
(e.g. family reunification) compared with Amsterdam, 
where most participants had migrated because of 
work/study. The region of origin also differed signifi-
cantly between the participants from Gelderland and 
Amsterdam (p < 0.001). Furthermore, participants in 
Gelderland more often originated from a country with 
an HBV prevalence of ≥ 2% compared with Amsterdam 
participants.
Prevalence and determinants of newly 
diagnosed HBV, HCV and HIV infections
In Gelderland, 29 of the 203 participants were anti-
HBc-positive (14.3%; 95% CI: 10.1–19.8%) and the prev-
alence of chronic HBV infections was 4.48% (9/201; 
95% CI: 2.37–8.29%). In two cases, HBsAg was not 
determined. Two of the 203 participants were anti-HCV-
positive (0.99%; 95% CI: 0.27–3.52%). All HBV and HCV 
infections in Gelderland were newly diagnosed.
In Amsterdam, one of the 256 participants had a 
chronic HBV infection (0.39% (1/256; 95% CI: 0.07–
2.18%). Three of 256 participants were anti-HCV-pos-
itive (1.17%; 95% CI: 0.40–3.39%) of whom one had 
a chronic HCV infection (0.39% (1/256; 95% CI: 0.07–
2.18%). Both participants in Amsterdam with a chronic 
HBV and HCV infection were previously diagnosed. The 
participant with chronic HBV infection reported that 
they had been successfully treated and were being 
monitored in their country of origin. The participant 
with chronic HCV infection had started treatment in the 
country of origin, but discontinued it there because of 
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side effects. This patient was referred to a Dutch hepa-
titis treatment centre and successfully completed HCV 
treatment approximately 6 months after screening. No 
HIV infections were found in Amsterdam.
Characteristics of all participants with a newly diag-
nosed chronic HBV infection (9/457; 1.97%; 95% 
CI: 1.04–3.70%) are shown in Table 2. In univariate anal-
yses, participants who migrated to the Netherlands for 
reasons other than work/study were more likely to have 
a newly diagnosed chronic HBV infection than those 
who migrated for work/study (4.3% vs 0.8%; OR = 5.45; 
95% CI: 1.12–26.60). Participants in Amsterdam were 
less likely to have a newly diagnosed chronic HBV infec-
tion than those in Gelderland (0% vs 4.5%; OR = 0.04; 
95% CI: 0.00–0.69). No other variables were statisti-
cally significantly associated with having a newly diag-
nosed chronic HBV infection.
Discussion 
In this project, about half (54%) of the migrants attend-
ing the existing compulsory TB entry screening at pub-
lic health services accepted additional HBV, HCV and 
HIV screening. The prevalence of chronic HBV infection 
(HBsAg-positive) and HCV exposure (anti-HCV-positive) 
in Gelderland was 4.48% and 0.99%, respectively, and 
all were newly diagnosed. The prevalence of chronic 
HBV infection in Amsterdam was 0.39%. The preva-
lence of HCV exposure (anti-HCV-positive) and chronic 
HCV infection (HCV RNA-positive) in Amsterdam was 
1.17% and 0.39%, respectively. All chronic HBV and 
HCV infections in Amsterdam were previously diag-
nosed. No HIV infections were found.
Surprisingly, we found a significant difference in the 
prevalence of newly diagnosed chronic HBV infec-
tions between Gelderland (4.48%) and Amsterdam 
(0%). There are several potential explanations. The 
background HBV prevalence in the countries of ori-
gin of Gelderland participants was higher compared 
with Amsterdam participants. However, in univariate 
analyses, background HBV prevalence was not asso-
ciated with newly diagnosed chronic HBV infection. 
In addition, those who migrated to the Netherlands 
for reasons other than work/study were more likely 
to have a newly diagnosed HBV infection, perhaps 
reflecting an increased risk among those with a lower 
socioeconomic status. The fact that more Gelderland 
participants migrated to the Netherlands for reasons 
other than work/study might therefore help explain 
the higher prevalence found among Gelderland par-
ticipants. The differences in country of origin and rea-
son for migration between participants in Gelderland 
and Amsterdam indicate that different areas in the 
Netherlands attract different groups of migrants, which 
is most probably due to work, study or housing oppor-
tunities in a given area or due to the migration history 
of family members. Another explanation for the varying 
prevalence of newly diagnosed chronic HBV infections 
might be differences in unmeasured HBV risk factors 
between participants from Gelderland and Amsterdam. 
Prior HBV vaccination was not among the exclusion cri-
teria in Amsterdam, but it was in Gelderland.
In a comparable study from Scotland, where an inte-
grated TB, HBV, HCV and HIV screening was only offered 
to international students, the prevalence of newly diag-
nosed HBV infections was also low (HBsAg prevalence: 
2.6%, prevalence of newly diagnosed HBV infections: 
1.3%, no HCV or HIV infections were found) [24]. The 
screening uptake found in both regions of our project 
was higher compared with the project in Scotland 
(35%) and compared with previous non-integrated HBV 
and HCV screening projects targeting migrants in the 
Netherlands (range: 7–42%) [9,10-18,24]. Uptake was 
lower compared with response rates for antenatal HBV 
and HIV screening of migrants in the Netherlands (HBV: 
99.99%, HIV: 99.8%) [25], however, pregnant women 
could be generally more interested in screening if its 
primary aim is to prevent transmission to the unborn 
child. Furthermore, antenatal HBV and HIV testing in 
the Netherlands are offered according to the opt-out 
principle (everyone gets tested unless they explicitly 
refuse). The opt-out approach substantially improves 
HIV testing rates not only among pregnant women but 
also among clients of outpatient clinics focussed on 
sexually transmitted infections [26,27]. Similarly, an 
opt-out testing strategy might improve response rates 
to integrated HBV, HCV and HIV screening at the TB 
departments.
We found that the most common reason for declining 
screening was having already been tested. This might 
be indicative of a group with adequate access to care 
in their country of origin, in which HBV, HCV and HIV 
screening might therefore yield fewer newly diagnosed 
infections. Our results suggest that adding HIV screen-
ing is acceptable to migrants, as we saw no statistically 
significant difference in uptake between Amsterdam, 
where HIV screening was included, and Gelderland, 
where it was not. Only one person opted out of the HIV 
testing.
Unfortunately, the resources needed to add HBV, HCV 
and HIV screening to the compulsory TB-entry screen-
ing were not measured. Whether adding HBV, HCV and 
HIV screening to the compulsory TB entry screening in 
the Netherlands will be cost-effective needs to be fur-
ther explored. A previous study from the Netherlands 
estimated that one-time-only, non-integrated HBV 
screening of all migrants from HBV-endemic countries 
(estimated background HBsAg prevalence: 3.35%), 
with a participation rate of 35%, was most probably 
cost-effective [28]. Although the overall HBV preva-
lence in our project was lower than 3.35%, overall HCV 
prevalence was low and no HIV infections were found, 
integrating HBV, HCV and HIV screening into the TB 
entry screening might also be cost-effective, as the 
programme costs of integrated screening programmes 
are expected to be lower compared with non-integrated 
screening. To further increase effectiveness, a pre-
screening selection of migrants based on risk factors 
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deserves exploration, e.g. reason for migration, coun-
try of origin, or HBV, HCV and HIV risk factors such as 
blood transfusion history and injecting drug use [29].
If HBV, HCV and HIV screening were to be integrated 
into the TB entry screening, it should be taken into 
account that not all migrants are registered with a GP 
or have a Dutch health insurance at the time of screen-
ing. Although registering with a GP is easy and all 
Dutch citizens (including legal migrants and regard-
less of health status) are entitled to Dutch health 
insurance, extra guidance is needed to make sure that 
HBV, HCV and HIV-diagnosed migrants register with 
a GP and get a Dutch health insurance, and that they 
will be successfully referred and linked to specialised 
care [30,31]. Also, additional screening for migrants is 
needed to reach HBV, HCV and HIV risk groups who are 
not required to have TB entry screening (e.g. migrants 
from countries with high endemicity for HBV, HCV or 
HIV but with low endemicity for TB). Alternatives such 
as case finding through GPs should be explored for 
effectiveness and acceptability.
Our project has several limitations. Firstly, as our 
objective was to study the acceptability and effec-
tiveness of HBV, HCV and HIV screening within the 
normal TB screening procedures, we decided not to 
measure HBV, HCV and HIV risk factors. Measuring 
HBV, HCV and HIV risk factors would have provided 
more insight into the usefulness of risk-based screen-
ing and could potentially have provided more insight 
into the differences between the prevalence of newly 
diagnosed chronic HBV infections between Gelderland 
and Amsterdam. Also, due to a low number of HBV 
infections, the analyses of demographic and migration 
characteristics as potential determinants of HBV were 
limited. Secondly, results of this project may not be 
generalisable to all migrants attending TB screening in 
the Netherlands, especially as we found regional differ-
ences in the characteristics and HBV prevalence of our 
populations and as migration flow changes over time. 
Finally, the inclusion criteria, recruitment procedures 
(the available translations and the timing of receipt of 
the project information) and screening procedure (in- 
or exclusion of HIV testing) differed slightly between 
the two regions. However, despite these small differ-
ences, uptake of screening between Gelderland and 
Amsterdam was similar.
Conclusion 
About half of the migrants visiting the five TB depart-
ments accepted HBV, HCV and HIV screening. The prev-
alence of newly diagnosed HBV infections was lower 
intermediate (2–4.99% [21]) in migrants screened in 
Gelderland, but no newly diagnosed HBV infections 
were found in Amsterdam. This regional difference prob-
ably reflects the differences in countries of origin and 
reasons for migration (which may be related to differ-
ences in social economic status) between participants 
in Gelderland and Amsterdam. The prevalence of newly 
diagnosed HCV infections was low in both regions, and 
no HIV infections were found. A more effective strat-
egy might be targeted, integrated TB, HBV, HCV and 
HIV screening for migrants, which includes prescreen-
ing selection based on risk factors and an opt-out test-
ing approach. Data and cost-effectiveness studies are 
needed for decision-making regarding the implementa-
tion of HBV, HCV and HIV screening that is integrated 
into entry screening at TB departments.
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